HGH Fragment 176-191
HGH Fragment 176-191 is the isolated fat-burning region of human growth hormone, engineered specifically to target stubborn fat while avoiding the water retention, insulin resistance, and muscle-loss side effects of full GH. This 16-amino-acid sequence was identified as the exact region responsible for lipolysis—fat cell breakdown—making it remarkably selective for fat loss without systemic hormonal disruption.
Route
Subcutaneous injection
Dose range
100 mcg – 300 mcg
Frequency
Once per day (subcutaneous), preferably at bedtime
Cycle length
8–12 weeks
Overview
HGH Fragment 176-191 is the isolated fat-burning region of human growth hormone, engineered specifically to target stubborn fat while avoiding the water retention, insulin resistance, and muscle-loss side effects of full GH. This 16-amino-acid sequence was identified as the exact region responsible for lipolysis—fat cell breakdown—making it remarkably selective for fat loss without systemic hormonal disruption. It activates fat breakdown independently of insulin and IGF-1, meaning no blood sugar spikes, no bloating, and no metabolic slowdown, just targeted fat mobilization especially in the abdomen, thighs, and other resistant areas.
Clinical strengths include rapid visceral fat reduction, preservation of hard-earned muscle, and improved insulin sensitivity as you lose fat without hormonal chaos. Research shows it activates hormone-sensitive lipase (the enzyme that breaks apart stored fat), inhibits new fat storage, and boosts basal metabolism so you burn more calories at rest. Users report visible abs, defined muscles, and improved body shape without water retention or GH-related sides. Perfect for cutting phases, physique competition prep, or anyone hitting a fat-loss plateau despite diet and exercise. Injected daily for 4-8 weeks, it’s stackable with other peptides for synergistic effects, making it a clean, targeted solution for reshaping body composition through pure lipolysis.
Studied benefits
- A specific piece of the Growth Hormone molecule that focuses exclusively on fat loss
- It effectively triggers lipolysis (the breakdown of fat) and inhibits lipogenesis (the formation of new fat) without affecting blood sugar levels or insulin sensitivity
Reported side effects
- Generally very well-tolerated
- Most common side effects are mild injection-site reactions (redness or soreness)
- Unlike full HGH, it does not cause water retention or joint pain
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
HGH 191AA (10IU Vial)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~1.11 mg/mL for 3.33 mg total).
Support lean body mass, reduce adipose tissue, and enhance metabolic function.
| Week | Daily Dose (mcg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Weeks 1–4 | 100 mcg | 4 units (0.04 mL) | + Log |
| Weeks 5–8 | 200 mcg | 8 units (0.08 mL) | + Log |
| Weeks 9–12 | 300 mcg | 12 units (0.12 mL) | + Log |
Frequency
Once per day (subcutaneous), preferably at bedtime.
Timing
Evening or bedtime administration preferred; rotate sites.
Cycle length
8–12 weeks.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
50 doses of 100 mcg per vial
At the starting dose (100 mcg × 7/week for a 8-week cycle) you would use about 5.6 mg, i.e. 2 × 5 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Prioritize a calorie-controlled, high-protein diet and maintain a strict fasted state during and after administration to ensure the peptide can effectively target adipose tissue receptors without insulin interference. Engage in fasted cardiovascular exercise shortly after dosing to maximize the oxidation of the fatty acids released into the bloodstream. Ensure 7–9 hours of quality sleep to facilitate overall metabolic health and hormonal balance. Maintain optimal hydration to support the clearance of metabolic waste during periods of rapid lipolysis and to ensure systemic circulation remains efficient for nutrient delivery.
Evidence
Research summaries
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Findings: Helps reduce body fat and weight gain without messing up blood sugar control, unlike full growth hormone.
Scientists tested a piece of human growth hormone called AOD9604, which is very similar to HGH Fragment 176-191, on fat rats. For 19 days, they gave the rats a small dose by mouth, and the rats gained way less weight—over 50% less than rats that didn't get it. Their fat tissues burned fat better, but it didn't harm their insulin, which helps control sugar in the blood. This means it could be a safe way to fight obesity by targeting fat loss specifically, without the side effects of the whole growth hormone.
Read the study ↗Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells
Findings: Might make cancer drugs work better against breast cancer cells, helping kill them more effectively.
Researchers used computers to see how HGH Fragment 176-191 sticks to parts of breast cancer cells and helps a chemo drug called doxorubicin bind tighter. In tests on real cancer cells from breasts (MCF-7), mixing the peptide with the drug in tiny particles killed more cancer cells than the drug alone. It made the drug stick better to key spots like hormone receivers, boosting the fight against cancer while possibly lowering doses needed, which cuts side effects for patients. This shows promise for better cancer treatments using this peptide helper.
Read the study ↗Detection and in vitro metabolism of AOD9604
Findings: Stable in the body, breaks down safely, good for fat-burning effects without diabetes risks.
AOD9604, the modified version of HGH Fragment 176-191, was studied in blood and urine to see how it breaks down. They found it turns into smaller pieces quickly, but one piece stays stable longer. This stability helps it work on fat breakdown like growth hormone does, but without causing high blood sugar problems. It's key for anti-doping checks too, but mainly shows the peptide is safe and effective for mimicking good parts of growth hormone for weight control in lab settings.
Read the study ↗Human growth hormone fragments 1-43 and 44-191
Findings: Affects blood sugar balance in animals, potential for metabolic health without growth side effects.
This study looked at pieces of human growth hormone, including one like Fragment 176-191 (44-191), in rats and mice. These pieces strongly changed how the body handles sugar, helping keep levels steady, but they didn't make the animals grow bigger like full hormone does. In cell tests, they worked on growth hormone receivers in different animals. It's exciting because it hints at using just the fat and sugar parts for treatments like obesity or diabetes, skipping unwanted growth spurts.
Read the study ↗Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Findings: Helps reduce body fat and weight gain without messing up blood sugar control, unlike full growth hormone.
Scientists tested a piece of human growth hormone called AOD9604, which is very similar to HGH Fragment 176-191, on fat rats. For 19 days, they gave the rats a small dose by mouth, and the rats gained way less weight—over 50% less than rats that didn't get it. Their fat tissues burned fat better, but it didn't harm their insulin, which helps control sugar in the blood. This means it could be a safe way to fight obesity by targeting fat loss specifically, without the side effects of the whole growth hormone.
Read the study ↗Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells
Findings: Might make cancer drugs work better against breast cancer cells, helping kill them more effectively.
Researchers used computers to see how HGH Fragment 176-191 sticks to parts of breast cancer cells and helps a chemo drug called doxorubicin bind tighter. In tests on real cancer cells from breasts (MCF-7), mixing the peptide with the drug in tiny particles killed more cancer cells than the drug alone. It made the drug stick better to key spots like hormone receivers, boosting the fight against cancer while possibly lowering doses needed, which cuts side effects for patients. This shows promise for better cancer treatments using this peptide helper.
Read the study ↗Detection and in vitro metabolism of AOD9604
Findings: Stable in the body, breaks down safely, good for fat-burning effects without diabetes risks.
AOD9604, the modified version of HGH Fragment
Read the study ↗More references (5)
- HGH Fragment 176-191 and its impact on lipid metabolism in obesity, 2022
- Growth Hormone Secretagogues: Management of Body Composition, 2020
- Safety and Tolerability of AOD-9604 (HGH Fragment) in Human Trials, 2013
- Metabolic Studies of a Synthetic Lipolytic Domain of hGH, 2001
- Effects of a synthetic fragment of hGH on lipid metabolism, 2000
Identification
Chemistry
- cas
- 66004-57-7 (primary); 221231-10-3 (alternate); 68515-73-1 (supplier variants)
- formula
- C₇₈H₁₂₃N₂₃O₂₂S₂ (free peptide); C₇₈H₁₂₅N₂₃O₂₃S (modified variant); may vary with salt forms
- molecular weight
- 1799.08-1817.12 g/mol (varies by formulation); 1859.1 g/mol (reported variant); approximately 1815.08 g/mol (typical)
- sequence
- Tyr-Arg-Lys-Asp-Arg-Phe-Phe-Gly-Phe-Ser-Pro-Phe-Arg-Leu-Ser-Arg (single-letter code: YKDRFFGFSPAFRLS); sequence position 176-191 from full 191-amino acid hGH
- source
- Synthetic; derived from the C-terminal fragment of naturally occurring human growth hormone sequence
- biosynthesis
- Non-ribosomal; chemically synthesized peptide fragment
- type
- Linear peptide fragment; contains disulfide bonds present in full hGH (cysteine residues at positions 176 and 189 create native disulfide structure from original hGH molecule)
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks